Boundless Bio Announces Results of 2026 Annual Meeting of Stockholders

On June 15, 2026, Boundless Bio, Inc. held its annual meeting of stockholders to vote on two key proposals. First, stockholders elected two Class II directors, James Christensen, Ph.D., and Jennifer Lew, to serve on the Board of Directors until the 2029 annual meeting of stockholders. Dr. Christensen received 9,287,096 votes for, while Ms. Lew received 9,271,084 votes for. Second, stockholders ratified the appointment of KPMG LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The ratification passed with 15,376,973 votes in favor. The filing also noted a change in the company's principal executive office address from San Diego to La Jolla, California. No clinical trial updates or material financial developments were reported in this filing.